Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease.

Res Rep Urol · 2018 · PMC5790095 · PMID 29417045

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

14 The overall results of the study suggest similar efficacy with carboplatin/gemcitabine compared to M-CAVI, with a higher ORR (41% for Carbo/Gem vs 30% for M-CAVI) that did not reach statistical significance and no difference in median OS (9 months with carbo/gem vs 8 months with M-CAVI) or median progression-free survival (PFS; 6 vs 4 months).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.